Active	Status	Sponsor type	Region	Phase	Filter
3 Active 2 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   - « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Pollio, Berardino
NCT05582993 / 2020-003304-13: A Study of Vonicog Alfa (rVWF) in Children With Severe Von Willebrand Disease (vWD)	Recruiting	3	24	Europe, Japan, US	Vonicog Alfa, TAK-577, Recombinant von Willebrand Factor (rVWF), Vonvendi-Veyvondi, ADVATE, Recombinant Factor VIII (rFVIII), Octocog Alfa	Takeda, Takeda Development Center Americas, Inc.	Von Willebrand Disease (VWD)	04/30	04/30
Protect-NOW, NCT03695978: Efficacy, Safety & Utilisation of Nuwiq, Octanate and Wilate in Previously Untreated & Minimally Treated Haemophilia A Patients	Recruiting	N/A	200	Europe, Canada, US, RoW		Octapharma	Haemophilia A	06/30	06/30

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Pollio, Berardino
NCT05582993 / 2020-003304-13: A Study of Vonicog Alfa (rVWF) in Children With Severe Von Willebrand Disease (vWD)	Recruiting	3	24	Europe, Japan, US	Vonicog Alfa, TAK-577, Recombinant von Willebrand Factor (rVWF), Vonvendi-Veyvondi, ADVATE, Recombinant Factor VIII (rFVIII), Octocog Alfa	Takeda, Takeda Development Center Americas, Inc.	Von Willebrand Disease (VWD)	04/30	04/30
Protect-NOW, NCT03695978: Efficacy, Safety & Utilisation of Nuwiq, Octanate and Wilate in Previously Untreated & Minimally Treated Haemophilia A Patients	Recruiting	N/A	200	Europe, Canada, US, RoW		Octapharma	Haemophilia A	06/30	06/30